The rationale underlying this approach was to allow peptides from tumor antigens, which are endogenous proteins, to associate with MHC class II molecules in the ER, similarly to what happens for MHC class I-peptide binding, and thus allow better recognition of putative tumor antigens by MHC class II-restricted CD4+ Th cells. This evidence concerns the gene CD4 and neoplasm.